This led to a reduction in cancer cell proliferation, which, in part, can be attributed to its ability to down-regulate the production of pro-inflammatory cytokines like TNF in CML patients [18]. This evidence concerns the gene TNF and chronic myelogenous leukemia, BCR-ABL1 positive.